New Ibogaine Study Under Development
The MAPS clinical research team met during our Psychedelic Science in the 21st Century conference to develop a new ibogaine outcome study. Principal Investigator Valerie Mojeiko and co-investigator Tom Kingsley Brown, Ph.D., will lead the new study. They will collect data from patients who undergo ibogaine treatment for opiate addiction at Pangea Biomedics in Tijuana, Mexico, in order to evaluate the long-term changes that follow ibogaine treatment. The team discussed details of the new protocol, one of which will add random urine tests as another assessment technique.
The previous ibogaine study sponsored by MAPS and led by John Harrison has ended, and we are currently evaluating the data. We are applying insights from our initial study to the design of the new protocol.